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Abstract
Constitutive MAPK activation silences genes required for iodide uptake and thyroid 
hormone biosynthesis in thyroid follicular cells. Accordingly, most BRAFV600E papillary 
thyroid cancers (PTC) are refractory to radioiodide (RAI) therapy. MAPK pathway inhibitors 
rescue thyroid-differentiated properties and RAI responsiveness in mice and patient 
subsets with BRAFV600E-mutant PTC. TGFB1 also impairs thyroid differentiation and has 
been proposed to mediate the effects of mutant BRAF. We generated a mouse model 
of BRAFV600E-PTC with thyroid-specific knockout of the Tgfbr1 gene to investigate the 
role of TGFB1 on thyroid-differentiated gene expression and RAI uptake in vivo. Despite 
appropriate loss of Tgfbr1, pSMAD levels remained high, indicating that ligands other 
than TGFB1 were engaging in this pathway. The activin ligand subunits Inhba and Inhbb 
were found to be overexpressed in BRAFV600E-mutant thyroid cancers. Treatment with 
follistatin, a potent inhibitor of activin, or vactosertib, which inhibits both TGFBR1 and the 
activin type I receptor ALK4, induced a profound inhibition of pSMAD in  
BRAFV600E-PTCs. Blocking SMAD signaling alone was insufficient to enhance iodide uptake 
in the setting of constitutive MAPK activation. However, combination treatment with 
either follistatin or vactosertib and the MEK inhibitor CKI increased 124I uptake compared 
to CKI alone. In summary, activin family ligands converge to induce pSMAD in Braf-mutant 
PTCs. Dedifferentiation of BRAFV600E-PTCs cannot be ascribed primarily to activation of 
SMAD. However, targeting TGFβ/activin-induced pSMAD augmented MAPK inhibitor 
effects on iodine incorporation into BRAF tumor cells, indicating that these two pathways 




 f TGF beta
 f BRAF
 f iodide uptake
28
Endocrine-Related Cancer  
(2021) 28, 391–402
This work is licensed under a Creative Commons 
Attribution 4.0 International License.
Printed in Great Britain
Published by Bioscientifica Ltd.
© 2021 The authors
https://doi.org/10.1530/ERC-21-0017
https://erc.bioscientifica.com
392K A Luckett, J R Cracchiolo 
et al.





Radioiodine is a key treatment modality for patients with 
recurrent or metastatic-differentiated thyroid cancer and 
is also widely applied in the post-operative adjuvant 
setting. Most papillary thyroid cancers (PTC), which are 
the most prevalent form of the disease, are associated 
with clonal non-overlapping activating mutations of 
genes encoding MAPK pathway signaling effectors, 
primarily point mutations of BRAF and of the three RAS 
genes, as well as fusions of receptor tyrosine kinases 
(Fagin & Wells 2016). There is an inverse correlation 
between the MAPK signaling flux of PTCs, as measured 
by its transcriptional output, and the expression of 
genes required for iodine uptake and thyroid hormone 
biosynthesis (Cancer Genome Atlas Research Network 
2014). BRAFV600E-mutant thyroid cancers have a high 
MAPK output because this class 1 BRAF-mutant signals 
as a monomer and is insensitive to the negative feedback 
effects of ERK on activated RAF dimers (Yao et al. 2015). 
Accordingly, they also have the most profoundly 
decreased thyroid differentiation score (TDS) (Cancer 
Genome Atlas Research Network 2014), a quantitative 
integrated readout of a set of thyroid differentiation 
markers, and tend to be more refractory to RAI therapy 
(Xing et al. 2005).
Treatment of well-differentiated thyroid cells with 
TGFB1 impairs TSH-induced expression of thyroid-specific 
genes such as Tg (thyroglobulin) and Slc5a5 (Nis) (Colletta 
et al. 1989). The Santisteban lab showed that pSMAD2/3 
binds to the thyroid lineage transcription factor PAX8 
and impairs its transactivation of the sodium iodide 
symporter (Nis), and that this is reversed by expression 
of SMAD7 (Costamagna et  al. 2004, Riesco-Eizaguirre 
et  al. 2009), which prevents SMAD2/3 activation by 
promoting degradation of the TGFβ receptor (Kavsak 
et al. 2000). Moreover, BRAFV600E-induced suppression of 
Nis expression was shown to be mediated by a TGFB1-
driven autocrine loop in PCCL3 (Riesco-Eizaguirre et  al. 
2009). This group also found that the inhibition of Nis 
transcription was MEK-independent, implying that 
redifferentiation is attainable in the setting of high 
constitutive MAPK activation. This is inconsistent with the 
evidence that RAF and MEK inhibitors rescue NIS mRNA 
levels and iodine incorporation in BRAF-mutant cell lines, 
mouse models and patients (Knauf et al. 2003, Liu et al. 
2007, Chakravarty et al. 2011, Ho et al. 2013, Rothenberg 
et al. 2015, Nagarajah et al. 2016). Nevertheless, BRAFV600E 
clearly increases TGFB1 expression and pSMAD in cell 
lines and mouse PTCs (Riesco-Eizaguirre et  al. 2009, 
Knauf et  al. 2011), prompting us to investigate the 
functional role of this pathway in a genetically accurate 
in vivo context.
By using a combination of genetic and pharmacological 
approaches, we found that pSMAD activation is increased 
in BRAF-mutant thyroid cancers, and that this is due to 
promiscuous engagement of activin and TGFβ family 
ligands with their corresponding receptors. Inhibition 
of pSMAD activation in vivo is insufficient to induce 
the cancer cells to redifferentiate in the context of 
constitutive MAPK activation. However, suppression of 
both MAPK and pSMAD pathways leads to enhancement 
of radioiodine uptake in cancer cells, an effect that could 
be leveraged for therapeutic benefit.
Materials and methods
Mouse models
Animals used in this study were maintained on a mixed 
strain background. Animal care and all experimental 
procedures were approved by the MSKCC Institutional 
Animal Care and Use Committee. The mouse lines were 
genotyped by Transnetyx, Inc. (Cordova, TN) using 
quantitative PCR or by PCR using primers described in 
Supplementary Table 1 (see section on supplementary 
materials given at the end of this article).
TPO-Cre mice (Kusakabe et  al. 2004) obtained 
from Dr Shioko Kimura (NCI) were bred with 
LSL-BrafV600E mice (Mercer et  al. 2005) obtained from 
Dr Catrin Pritchard (University of Leicester, UK) to 
generate TPO-Cre/LsL-BrafV600E (Braf) mice, resulting 
in thyroid-specific knock-in of oncogenic Braf (Franco 
et al. 2011). Tgfbr1f/f (TβR1) mice (Larsson et al. 2003), a 
generous gift from Dr Yosuke Mukoyama (NIH/NHLBI), 
were bred with LSL-BrafV600E and TPO-Cre to generate 
LSL-BrafV600E/Tgfbr1f/f and TPO-Cre/Tgfbr1f/f, 
respectively. Experimental TPO-Cre/LSL-BrafV600E/
Tgfbr1f/f (Braf/TβR1) mice were generated by breeding 
TPO-Cre/Tgfbr1f/f with LSL-BrafV600E/Tgfbr1f/f.
Generation of Tre-shTgfbr1 mice
The shRNAs to Tgfbr1 and Tgfbr2 were designed using 
splashRNA (splashrna.mskcc.org) (Pelossof et  al. 2017) 
and cloned into the pMSCV retrovirus expression vector. 
Retroviral particles expressing the shRNAs were generated 
as previously described (Dow et al. 2012) and used to infect 
a TPO-Cre/BrafV600E PTC cell line. Quantitative RT-PCR was 
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used to determine knockdown efficiency and Western 
blotting for pSMAD to evaluate efficacy for blocking 
TGFB1-induced SMAD activation (Supplementary Fig. 1D, 
E and F). Tgfbr1 shRNA #6, the most effective in blocking 
TGFB1-induced pSMAD (Supplementary Fig. 1D, E and 
F), was subcloned into the TGMP vector and used to 
target Tre-shTgfbr1 into the Cola1-homing cassette (CHC) 
in ESCs derived from TPO-Cre/LSL-BrafV600E/RIK/CHC 
mice using recombination-mediated cassette exchange 
(Premsrirut et al. 2011, Dow et al. 2012). The ESC clones 
confirmed to have single copy of Tre-shTgfbr1 targeted to 
the CHC were microinjected into blastocysts produced 
from NCI C57BL/6-cBrd/cBrd/Cr (C57BL/6 albino) mice 
and implanted into CD-1 pseudopregnant mothers 
enabling the production of chimeric pups. Chimeric 
pups were bred to generate TPO-Cre/RIK/Tre-shTgfbr1 
mice and experimental TPO-Cre/BrafV600E/RIK/Tre-shTgfbr1 
(Braf/shTβR1) animals generated by crossing them with 
LSL-BrafV600E. Animals were fed doxycycline-impregnated 
chow (TD01306, Envigo) to induce expression of the 
Tgfbr1 shRNA and the appropriate knockdown of Tgfbr1 
was confirmed by quantitative RT-PCR.
Generation of mouse papillary thyroid cancer 
cell lines
PTCs from Braf, Braf/TβR1 and Braf/shTβR1 mice were 
collected, washed with 1× PBS, minced and placed in 
digestion medium (MEM with 112 U/mL collagenase type 
I, 1.2 U/mL dispase and pen/strep). Minced tissues were 
incubated at 37°C for 45–60 min and then washed twice 
with Coon’s F12 containing 0.5% bovine brain extract 
(BBE) (Hammond Cell Tech) and pen/strep/glutamine 
(PSG) (Gemini Bio Products). Cells were resuspended 
in Coon’s F12 containing 0.5% BBE and PSG and then 
plated in CellBind plates (Corning). After culturing for 
7–10 days, the culture medium was changed to growth 
medium (Coon’s F12 containing 5% fetal bovine serum 
(FBS)(Omega Scientific), 0.5% BBE and PSG). Cells were 
passaged for at least 1 month and the thyroid cancer 
origin confirmed by expression of BRAFV600E prior to use.
Reagents
EW7197 (Vactosertib, Catalog No.S7530) and SD208 
(Catalog No.S7530) were purchased from SelleckChem. 
CH5126766 (CKI) was from Chugai Pharmaceutical 
Co. Follistatin was purchased from Shenandoah 
Biotechnologies Inc. The TGFB1 neutralizing antibody 
1D11 and its isotype control were obtained from the 
MSKCC MAB Core.
For in vivo experiments, CKI was dissolved in 2 
hydroxypropyl-β-cyclo-dextrin and administered once 
daily by oral gavage at a dose of 3.0 mg/kg. EW7197 was 
dissolved in artificial gastric fluid formulation (95 mM HCl, 
38 mM NaCl and 3.6 mg/mL pepsin) and administered 
once daily by oral gavage at a dose of 25 mg/kg. Follistatin 
was dissolved in sterile H2O and administered once 
daily by i.p. injection at a dose of 25 µg/kg. The TGFB1 
neutralizing antibody 1D11 and isotype control were 
suspended in sterile saline and administrated once every 
2 days at a dose of 10 mg/kg.
RNA isolation and quantitative RT-PCR
Thyroid lobes were surgically removed and immediately 
placed in liquid N2. Cell lines were scraped into PBS, washed 
once with PBS and the cell pellet used for RNA isolation. 
RNA was isolated using TRIzol (Invitrogen) or RNAeasy 
(Affymetrix) and 100–500 ng was reverse transcribed with 
SuperScript III (Invitrogen) in the presence of random 
hexamers to generate cDNA. Quantitative PCR using the 
cDNA as a template was done using Power SYBR Green 
PCR Master Mix (Applied Biosystems) and primer pairs for 
mouse β-actin, Tgfbr1, Tgfbr2, Tshr, Tg, Nis, Tpo, Pax8, and 
Dusp5 (Supplemental Table 1). The cycle threshold values 
for β-actin and the target genes were determined with 
a 7500 real-time PCR instrument (Applied Biosystems) 
and used to calculate the β-actin normalized relative 
expression using the QGENE program (Tomas et al. 2012).
124I PET imaging
Imaging was performed using an R4 microPET scanner 
(Concorde Microsystems) as previously described 
(Chakravarty et  al. 2011, Nagarajah et  al. 2016). Briefly, 
mice were gavaged with 2.6–3.5 MBq (70–94 μCi) 
of Na124I and were imaged 24 and 72 h later under 
inhalational isoflurane anesthesia at 1.5 L/min. List-mode 
data were acquired for 5 min using an energy window of 
250–750 keV and a coincidence timing window of 6 ns, 
histogrammed into 2D projected data by Fourier 
rebinning, and reconstructed by filtered back-projection 
using a cut-off frequency equal to the Nyquist frequency. 
Image visualization and analysis were performed 
using ASIPro VM software (Concorde Microsystems) 
by drawing a 3D volume of the target lesions to derive 
the activity concentrations to the two different time 
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points, which in turn was used to calculate a maximum 
activity concentration by applying an empirical model 
as previously described (Jentzen et al. 2008). The activity 
concentration was corrected for partial volume effects 
using a recovery coefficient derived from previously done 
phantom studies.
Immunostaining
Mouse thyroids dissected from surrounding tissues were 
fixed in 4% paraformaldehyde, embedded in paraffin, 
sectioned, and stained with hematoxylin and eosin 
(H&E). Sections were also immunostained for CD45. H&E 
and IHC for CD45 were performed by the MSK Molecular 
Cytology Core Facility.
Co-immunofluorescent staining for NIS 
and Pan-cadherin
For immunofluorescence staining, tissue sections 
deparaffinized and permeabilized with 0.3% Triton were 
subjected to heat-induced epitope retrieval using citrate-
based antigen unmasking solution at pH6 (H-3300; Vector 
Laboratories). Sections were blocked in PBS containing 
3% BSA and 10% normal donkey serum (017-000-121; 
Jackson Labs) and incubated with rabbit anti-Rat SLC5A5 
(kindly provided by Dr Nancy Carrasco, Vanderbilt School 
of Medicine), followed by A647 labeled donkey anti-rabbit 
secondary antibodies (A31573; Invitrogen) and sequentially 
co-stained with A546 labeled pan-cadherin antibody (Sc-
515872; Santa Cruz). Z-stack scans of the slides were taken 
with Pannoramic P250 Flash scanner (3DHistech, Hungary) 
using 20×/0.8NA objective lens. Regions of interest around 
the tissues were then drawn and max projection images 
were exported as .tif files using Caseviewer (3DHistech, 
Hungary). Images were analyzed using ImageJ/FIJI (NIH, 
USA) where thresholding and watershedding were used to 
segment the nuclei in the DAPI channel. NIS expression at 
the plasma membrane was determined by thresholding the 
A647/A546 channel and quantifying the co-localization 
fluorescence intensity at the membrane, and normalizing 
this to the DAPI/cell counts across the sections.
Western blotting
Mouse thyroid cancer cell lines were plated in CellBind 
plates in Coon’s F12 with 5% FBS, 0.5% BBE and PSG 
and incubated for 24–48 h. Medium was then switched 
to Coon’s F12 with 0.1% BSA and PSG and incubated for 
24–48 h. Cells were then washed with ice-cold PBS and 
harvested by scraping and centrifugation (1000 g for 4 
min at 4°C). The cell pellets were resuspended in a lysis 
buffer consisting of 10 mM Tris-HCl (pH 7.5), 5 mM 
ETDA, 4 mM EGTA, 1% Triton ×100, protease inhibitor 
cocktail (Sigma) and phosphatase inhibitor cocktail I and 
II (Sigma). Cells were placed on ice for 10 min and lysed 
by passing through a p200 tip. Cell debris was removed 
by centrifugation (18,000 g for 15 min at 4°C) and the 
supernatant was collected. Frozen tissues were placed in 
lysis buffer and then ground with a Polytron homogenizer. 
Lysates were centrifuged to removed debris (18,000 g for 
15 min at 4°C) and supernatant was collected. Protein 
concentration for all lysates was determined using the 
MicroBCA kit (Thermo Fisher Scientific). Ten to fifty 
micrograms of protein lysate was subjected to SDS-PAGE 
and transferred to PVDF membranes (VWR). The 
membranes were probed with the indicated antibody 
and the target protein detected by incubating with 
species-specific horseradish peroxidase conjugated IgG’s 
(Santa Cruz) or IRDye fluorophores and then with ECL 
reagent (Amersham Biosciences). HRP probed blots 
were developed using the ECL reagent (Amersham 
Biosciences) and the signal captured using X-ray films or 
with the KwikQuantTM Imager (http://kindlebio.com/
index.php). IRDye-probed blots were imaged using the 
LICOR Odyssey imaging system (Licor Biosciences). The 
following antibodies were used: from Cell Signaling pERK 
(9101), ERK (9102), pSMAD2S465/467 (3101S) and Vinculin 
(13901S), from Sigma β-actin (A2228), from Santa Cruz 
SMAD2/3 (sc-8332), from Thermofisher pSMAD2S465/467 
(44-244G), from Abcam pSMADT8; from Novus NOX4 
(NB110-58849). ImageJ was used to quantify band density.
Human clinical trials
The trials NCT02456701, NCT01947023 and NCT02145143 
were performed after approval by the MSKCC Institutional 
Review Board (IRB numbers 15-046, 13-061 and 14-031, 
respectively). Written informed consent was obtained 
from all patients in these studies. Patients received either 
vemurafenib 960 mg or dabrafenib 150 mg orally twice 
daily and had sequential biopsies of the same index lesion 
at baseline (prior to drug) and at 2 weeks while on either 
vemurafenib or dabrafenib. RNAseq was performed on all 
samples as described (Dunn et al. 2019).
Datasets and TGFβ family ligand score (TLS)
NCBI GEO human datasets GSE29265, GSE33630 
(Dom et  al. 2012, Tomas et  al. 2012) and GSE65144 
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(von Roemeling et  al. 2015) were downloaded and 
imported into Partek Genomic suites for normalization and 
expression analysis. Normalized expression data derived 
from RNAseq of PTCs in the THCA TCGA dataset (Cancer 
Genome Atlas Research Network 2014) were obtained from 





TGFβ family ligand score is the average log2 fold change 
of Tgfb1, Tgfb2, Tgfb3, Inhba and Inhbb compared with the 
median of all samples. The TGFβ transcriptional output 
score was determined by calculating the average fold 
change for all mRNAs in the gene set. The TGFβ gene set 
consisted of genes found regulated by TGFβ (Coulouarn 
et  al. 2008) that were also upregulated in mouse 
BRAFV600E-PTCs compared to normal thyroid and included 
the following mRNAs: GNG13, HMGA2, MOSPD3, PCDH1, 
PDLIM7, PRG4, TGFBR1, TNK2, UBR2 and ZSWIM4.
Statistical analysis
The statistical software GraphPad-Prism (version 8.0; 
GraphPad Software, Inc.) was used to analyze the data, 
compute the Pearson correlation coefficients and calculate 
Figure 1
SMAD pathway activation in BRAFV600E-induced 
PTCs. (A) Western blot of normal thyroid and 
tumor lysates from TPO-Cre/LSL-BrafV600E (Braf) 
mice probed with antibodies to the indicated 
proteins. (B) Western blot of tumor tissues from 
Braf mice treated with vehicle or the MEK inhibitor 
CKI127 (CKI) probed for the indicated targets. 
Each lane corresponds to an individual mouse 
PTC (n = 4 per group). (C) TGFβ-SMAD 
transcriptional output scores of normal thyroid 
tissues compared to biopsy samples from 
patients with RAI-refractory thyroid cancers taken 
prior to and while on treatment with the RAF 
kinase inhibitors dabrafenib (blue) or 
vemurafenib (red) for 2 weeks. Each line depicts 
paired biopsy results from the same lesion prior 
to and while on drug. (D) Quantitative RT-PCR of 
thyroid differentiation markers in tumors from 
panel B. (E) Interactions between the MAPK 
pathway and TGFβ signaling in thyroid cancer. 
Oncogenic BRAF induces dedifferentiation in part 
by ERK-induced silencing or inactivation of lineage 
transcription factors and by interfering with 
TSH-induced cAMP signaling (Mitsutake et al. 
2005) (not shown). BRAFV600E also increases tumor 
cell secretion of TGFB1, leading to SMAD 
impairment of transactivation of thyroid-specific 
genes by the lineage transcription factor PAX8. 
Oncogenic BRAF also induces pERK 
phosphorylation at the T8 residue of SMAD, 
promoting its additional phosphorylation and 
activation by the TGFB1 receptor.
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P-values using unpaired two-tailed Student's t-tests. All 
data for quantitative RT-PCR, Affy expression array values, 
immunofluorescence image quantification and Western 
blots are represented as mean ± s.e.m.
Results
SMAD activation in BRAFV600E-driven PTCs is regulated 
via MAPK
To determine whether the TGFβ/SMAD pathway 
is activated in BRAFV600E-driven PTC in vivo, we 
performed pSMAD Western blots in tumor lysates from 
TPO-Cre/LSL-BrafV600E mice, which develop thyroid 
cancers with high penetrance by 5 weeks of age (Franco 
et  al. 2011). As shown in Fig. 1A, there was a marked 
increase in pSMAD in BRAFV600E-PTCs compared to 
normal thyroid. Treatment of mice with 1.5 mg/kg of the 
MEK inhibitor CH5126766 (CKI), which binds to MEK 
and places it in an inactive conformation bound to RAF 
(Ishii et al. 2013), potently blocked MAPK signaling and 
reduced pSMAD levels as well as expression of the TGFβ 
downstream target NOX4 (Fig. 1B) (Azouzi et  al. 2017). 
MEK inhibition also reduced phospho-SMAD T8 levels 
(Fig. 1B), which has been previously shown to be required 
for optimal TGFβ signaling in mouse thyroid follicular 
cells (Knauf et al. 2011). In humans, BRAFV600E-driven PTCs 
had increased SMAD transcriptional output compared to 
normal thyroid, which was reduced by treatment with 
RAF inhibitors (Fig. 1C). As previously demonstrated, CKI 
increased the expression of genes involved in thyroid 
hormone biosynthesis (Fig. 1D) (Nagarajah et  al. 2016). 
Hence, MAPK and pSMAD signaling are markedly increased 
in PTC driven by oncogenic BRAF, and the activity of both 
these pathways is MEK-dependent. Both could converge 
to impair the thyroid-differentiated function of the cancer 
cells, but their relative contribution to these effects has 
not been established (Fig. 1E).
Role of TGFβ/SMAD in BRAFV600E-induced thyroid 
differentiation in vivo
To explore the role of TGFB1 on thyroid-differentiated 
gene expression in thyroid tumors, we first tested the 
TGFB1-neutralizing MAB 1D11 and the TGFBR1 (TβR1) 
Figure 2
TβR1 knockout in mouse BRAFV600E-PTCs is 
insufficient to inhibit SMAD activation in vivo. (A) 
Schematic design of the transgenic lines used in 
this study and of their recombination when 
crossed with TPO-Cre mice: (1) Lsl-BrafV600E; (2) 
TβR1f/f and (3) tetO-shTβR1/RIK. (B) β-actin 
normalized expression of TβR1 mRNA in thyroid 
tissues of the indicated mouse lines as 
determined by quantitative RT-PCR (n = 4/group). 
*P < 0.05, **P < 0.005, ns = not significant. (C) 
Western blots for pSMAD and pERK in lysates 
from normal thyroid or PTCs from Braf, Braf/TβR1 
and Braf/shTβR1 mice. (D) Western blots of cell 
lines derived from PTCs of Braf, Braf/TβR1, and 
Braf/shTβR1 mice treated with vehicle or 1 ng/mL 
TGFβ1 for 1 h. Cells treated with dox were 
incubated for 3 days prior to collection.
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kinase inhibitor SD-208 in cell lines derived from mouse 
BRAFV600E-PTCs, where both effectively blocked the TGFB1-
induced SMAD2/3 phosphorylation (Supplementary Fig. 
1A). For in vivo experiments, we chose to test the 1D11 
antibody, because SD-208 has inhibitory effects on other 
kinases besides TβR1 (Tandon et  al. 2015). Treatment of 
mice with a 1D11 schedule known to block the TGFB1 
activity in vivo (Biswas et al. 2011) did not inhibit pSMAD 
in mouse BRAFV600E-PTCs (Supplementary Fig. 1B) or 
enhance the radioiodine uptake (Supplementary Fig. 1C). 
As this may have been due to the PK of the antibody in 
the tumor, we generated mouse models of BRAFV600E-
PTC with thyroid-specific knockout of the TgfβR1 gene, 
TPO-Cre/LSL-BrafV600E/TβR1fl/fl (Braf/TβR1) or, to avoid 
confounding effects of loss of the receptor during 
development, through post-natal dox-inducible 
expression of a TβR1 shRNA. We validated a series of TβR1 
hairpins in vitro, and selected TβR1 shRNA#6 to generate 
the mouse model TPO-Cre/LSL-BrafV600E/TetO-GFP_shTβR1/
RIK (Braf/shTβR1) (Fig. 2A and Supplementary Fig. 1D, 
F). The penetrance and histological characteristics of the 
PTCs in Braf/TβR1 and Braf/shTβR1 was indistinguishable 
from those of Braf mice (not shown). Despite appropriate 
knockdown of TβR1 with either model (Fig. 2B), pSMAD 
levels remained high in thyroid cancer tissues (Fig. 2C), 
and there was no significant increase in expression of 
thyroid differentiation markers (Supplementary Fig. 1G). 
Using cell lines derived from PTCs of Braf/shTβR1 and 
Braf/TβR1 mice, we found that the loss of TβR1 effectively 
blocked TGFB1-induced SMAD activation in vitro (Fig. 
2D). We concluded that Smad activation in this in vivo 
context was at least in part TβR1-independent.
Activins induce SMAD in BRAFV600E-induced 
thyroid cancers
The lack of SMAD inhibition by blocking TGFB1 or 
TGFBR1 in vivo suggested that other ligands of the TGFβ 
family might be engaging in this pathway. Activins are 
disulfide-linked homodimers or heterodimers of primarily 
two β-subunits, βA and βB, which are transcribed from 
the Inhba and Inhbb genes, respectively. They activate 
SMAD2/3 signaling via the activin type 1 receptor ALK4. 
Expression array data from normal mouse thyroid and 
Figure 3
Blocking both ALK4 and ALK5 is required to 
completely inhibit SMAD activation in BrafV600E-
induced PTCs. (A and B) Expression of the Tgfβ 
family ligands from Affymetrix expression arrays 
in (A) mouse and (B) human normal thyroids and 
PTCs. (C) Pearson correlation coefficient between 
the integrated TGFβ family ligand score (TLS) and 
TDS using the TCGA PTC dataset (Cancer Genome 
Atlas Research Network 2014). (D) Western blots 
of thyroid tumor lysates from Braf mice treated 
with EW7197 and of Braf/TβR1 mice treated  
with follistatin.
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BRAFV600E-PTCs showed Inhbb expression to be increased 
by >15-fold, as compared to a <3-fold increase in Tgfb1 
(Fig. 3A). On average human PTCs have a three- to four-
fold upregulation of the TGFβ family ligand mRNAs, with 
INHBA, TGFB1 and INHBB being the most prominent (Fig. 
3B and Supplementary Fig. 2A). Analysis of the TCGA 
dataset of PTC found an inverse correlation between 
the expression of either INHBA, INHBB, TGFB1, TGFB2 
or TGFB3 with the thyroid differentiation score (TDS). 
The reciprocal relationship with TDS was even stronger 
when compared with an integrated TGFβ ligand score 
encompassing expression levels of all five TGFβ family 
members (Fig. 3C).
Treatment of cell lines derived from Braf and Braf/TβR1  
mouse PTCs with activin AB markedly induced 
SMAD phosphorylation. Hence, SMAD activation in 
BRAFV600E-PTC cells can be induced via TβR1 (Alk5) or 
Acvr1b (Alk4) receptors, which is blocked by the dual 
ALK4 and ALK5 inhibitor EW7197 (vactosertib) (Fig. 3D).
To investigate the roles of activin and TGFB1 on SMAD 
activation in vivo, tumor-bearing Braf and Braf/TβR1 mice 
were treated with EW7197 or with follistatin, a potent 
inhibitor of several TGFβ family ligands (primarily activin 
and to a lesser extent BMPs, myostatin, and possibly TGFB3 
– but not TGFB1 or 2) (Nogai et al. 2008, Sepporta et al. 
2013). Treatment of Braf mice with EW7197 or follistatin 
effectively decreased pSMAD in the PTCs. Follistatin had 
a greater inhibitory effect on SMAD phosphorylation in 
PTCs from Braf/TβR1 as compared to Braf mice, indicating 
that both activin and Tgfβ co-regulate this pathway in 
these tumors (Fig. 3E).
To explore the role of SMAD in BRAFV600E-induced loss 
of iodide uptake in PTCs, Braf mice were treated with a 10 
days course of EW7197 or follistatin. Quantitative 124I-PET 
scans were performed prior to therapy and at days 7–10 
(Schema in Fig. 4A). EW7197 or follistatin monotherapy 
had no effect on 124I uptake in PTCs of either Braf or 
Braf/TβR1 mice. Accordingly, these drugs failed to rescue 
expression of Nis or any other thyroid differentiation 
marker in PTCs from either mouse model (Fig. 4).
We next examined whether SMAD inhibition further 
increased the iodide uptake induced by CKI. 124I PET 
imaging was performed prior to and while on treatment 
with CKI alone or in combination with the SMAD pathway 
inhibitors (Fig. 4A). Treatment with CKI caused a greater 
increase in 124I uptake in Braf/TβR1 compared to Braf mice 
(Fig. 4B). EW7197, which inhibits pSMAD profoundly in 
BRAFV600E-PTCs (Fig. 3C), also augmented the effects of 
CKI in Braf mice. Accordingly, there was a trend toward 
higher iodine uptake in Braf/TβR1 mice treated with the 
combination of follistatin and CKI compared to CKI 
alone. Taken together, combined blockade of ALK4 and 
ALK5 by pharmacological targeting alone (EW7197) or 
in combination with genetic ablation (follistatin + TβR1 
knockout) cooperates with MAPK inhibition to augment 
iodine uptake in Braf-mutant PTC.
Potent inhibition of pSMAD with either EW7197 in 
Braf mice or follistatin in Braf/TβR1 mice did not increase 
Nis, Tpo, Tg, or Pax8 mRNA levels, consistent with their 
lack of effect on iodide uptake (Fig. 4C). By contrast, 
treatment with CKI markedly increased all four markers. 
When CKI was combined with EW7197, there was a 
trend toward higher Nis and Tshr mRNA. CKI restored 
NIS protein to levels approaching those seen in normal 
thyroid, but the addition of EW7197 did not result in 
further augmentation (Fig. 4D and Supplementary Fig. 
3A). TGFβ has been shown to block the recruitment of 
immune cells to the tumor microenvironment (Tauriello 
et  al. 2018). Treatment of Braf mice with EW7197 or 
CKI + EW7197 did not increase CD45+ cell infiltration 
(Supplementary Fig. 3B), indicating that decreased tumor 
cell purity was unlikely to account for the lack of clear 
increase in thyroid differentiation markers in the tissue 
extracts. SMAD activation has been shown to reduce 
plasma membrane localization of NIS via upregulation 
of NOX4 (Azouzi et al. 2017). We tested this by IHC for 
NIS in tumors from Braf mice treated with vehicle, CKI 
or CKI + EW7197. CKI markedly increased membrane-
localized NIS compared to vehicle, which was not further 
augmented with the CKI + EW7197 combination (Fig. 4E 
and Supplementary Fig. 3C).
Discussion
PTCs driven by BRAFV600E have a greater frequency of 
nodal recurrences and are usually refractory to RAI 
treatment (Nikiforova et al. 2003, Elisei et al. 2008, Xing 
et  al. 2013). They are also overrepresented in FDG-PET 
positive metastatic disease (Ricarte-Filho et al. 2009). The 
relative resistance to 131I is explained by the disruption 
in expression of NIS and other thyroid-specific genes 
that are required for the incorporation of iodine into 
thyroid cells (1;2). Multiple mechanisms that are not 
mutually exclusive have been proposed to explain these 
effects: (1) BRAF activation inhibits PAX8 expression, a 
paired domain lineage transcription factor that regulates 
transcription of NIS and other thyroid-specific genes. 
(2) NKX2-1, a transcription factor essential for thyroid-
differentiated gene expression is phosphorylated by ERK, 
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which disrupts its ability to transactivate target genes 
(Missero et al. 2000). (3) Expression of BRAFV600E increases 
TGFB1 secretion in rat thyroid PCCL3 cells creating an 
autocrine loop that activates SMADs (Riesco-Eizaguirre 
et al. 2009), which in turn bind to PAX8 and impair its 
transactivation of the Nis gene promoter (Costamagna 
et  al. 2004). This induction of the TGFB1 autocrine 
loop by BRAFV600E in PCCL3 cells was shown to be MEK-
independent (Riesco-Eizaguirre et al. 2009).
The objective of this study was to determine the role of 
the TGFβ signaling pathway on thyroid differentiation in 
genetically accurate models of BRAFV600E-induced thyroid 
cancer in vivo. We found that SMAD phosphorylation 
was induced in mouse BRAFV600E-PTCs, and that a TGFβ 
transcriptional output signature was present in advanced 
RAI-refractory human BRAF-mutant thyroid cancers. We 
employed pharmacological and genetic approaches to 
target TGFβ signaling in the mouse models and found 
Figure 4
Co-inhibition of ALK4 and 5 in combination with MAPK blockade increases 124I uptake in Braf mice. (A) Schema for mouse experiments testing effects of 
CKI and/or EW7197 or follistatin on 124I incorporation into thyroid tumors from the indicated mouse models. (B) Fold-change in maximum 124I uptake in 
Braf and Braf/TβR1 mice treated with CKI, EW7197 or follistatin or the indicated combinations (*P < 0.05, **P < 0.01). (C and D) Quantitative RT-PCR (C) and 
Western blots (D) of tumor tissues from B (collected after second 124I PET study). (E) Immunofluorescent staining for NIS and pan-cadherin in tumors from 
mice treated as indicated in (A).
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that either approach effectively blocked TGFβ signaling 
in cell lines derived from the murine BRAFV600-PTCs but 
failed to do so in vivo. We found that other ligands in the 
TGFβ family were activating SMAD in vivo, which was 
buttressed by evidence of marked upregulation of Inhbb 
in BRAFV600E-PTCs. Accordingly, SMAD phosphorylation 
was inhibited in the PTCs by follistatin, an activin 
inhibitor. However, follistatin was only able to completely 
block pSMAD activation in mice with thyrocyte-specific 
genetic ablation of TβR1, indicating that both activin and 
TGFβ play a role in SMAD activation, with activin being 
dominant. We, therefore, chose the ALK4/5 inhibitor 
EW7197 to explore the role of SMAD activation on iodide 
uptake in mouse BRAFV600E-driven PTCs, leading to the 
conclusion that potent inhibition of SMAD alone was 
insufficient to restore expression of genes involved in 
thyroid hormone production or iodide uptake.
We previously showed that both BRAFV600E-PTC cells 
and tumor-associated macrophages contribute TGFB1 
to the tumor microenvironment (Knauf et  al. 2011). 
RNAseq of flow-sorted PTC cells from the TPO-Cre/LsL-
BrafV600E model used in this paper showed that Tgfb1 and 
Activin mRNA levels are higher in the BRAFV600E-PTC cells 
compared to normal thyroid follicular cells (not shown). 
We do not know which cell types, other than BRAFV600E-
PTC cells, contribute to the intratumoral pool of activin.
Potent MAPK pathway blockade promotes 
redifferentiation and increased iodide uptake in BRAFV600E-
driven thyroid cancer (Nagarajah et  al. 2016). Here, we 
show that this is associated with a decrease in SMAD 
activation, which is likely due to a reduction in ERK-
dependent phosphorylation of the threonine 8 residue 
of SMAD. Phosphorylation at this site by MAPK amplifies 
the activation of SMAD by ligand-bound TGFβ family 
receptors (Wrighton et al. 2009, Knauf et al. 2011). These 
convergent effects on SMAD may explain the increase in 
iodide uptake in Braf mice treated with the combination 
of EW7197 and CKI compared to CKI alone. However, 
MAPK activation suppresses the differentiation program 
largely through SMAD-independent mechanisms, since 
potent inhibition of SMAD failed to restore thyroid-
differentiated gene expression in the setting of persistent 
MAPK pathway activation. This likely explains why 
the treatment combination only resulted in a trend 
toward increased Nis and Tshr mRNA compared to MEK 
inhibition alone.
In summary, activation of the MAPK pathway by 
BRAFV600E promotes SMAD activation in vivo through 
TGFβ and activin-induced pathways. Increased expression 
of TGFβ and activin ligands is common in PTCs and this 
is inversely correlated with an integrated transcriptional 
output score associated with thyroid differentiation. 
TGFβ-induced signaling through SMAD has been shown 
to suppress the expression of NIS and other thyroid 
differentiation markers in BRAF-WT thyroid cells 
(Colletta et  al. 1989, Nicolussi et  al. 2003, Costamagna 
et  al. 2004). However, signaling via SMAD is not the 
primary mechanism for suppression of thyroid-specific 
gene expression or loss of iodide uptake in the context 
of MAPK activation in vivo, as inhibition of SMAD alone 
did not improve any of these biomarkers. The precise 
mechanism underpinning the additive effect of SMAD 
and MEK inhibition on iodide uptake is unclear. It was not 
associated with clear differences in the expression of NIS. 
NIS abundance and membrane localization are only some 
of the variables that impact iodide incorporation (others 
include iodide organification and iodide efflux, which we 
did not assess).
The enhancement of iodine uptake may reflect 
the close interplay between these two pathways, 
which mutually reinforce overlapping effects on the 
thyroid-differentiated state during dynamic changes 
in their respective signaling outputs. The translational 
implication of these findings is intriguing and has not 
been explored so far. Any clinical trials looking into 
synergistic effects of blocking SMAD and MAPK pathways 
should select agents that target both ALK4 and ALK5 and 
consider using them for short intervals because of the 
potential tumor-promoting effects of SMAD inhibition 
in cancer.
Supplementary materials
This is linked to the online version of the paper at https://doi.org/10.1530/
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